- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$237.59

Market cap

$61.78B

P/E Ratio

22.93

Dividend/share

N/A

EPS

$10.36

Enterprise value

$56.97B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

The gross profit has soared by 68% YoY and by 11% from the previous quarter

VRTX's revenue has soared by 66% YoY and by 11% QoQ

VRTX's debt is down by 10% YoY but it is up by 4.7% QoQ

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

260.04M

Market cap

$61.78B

Enterprise value

$56.97B

Price to earnings (P/E)

22.93

Price to book (P/B)

7.61

Price to sales (P/S)

10.33

EV/EBIT

19.24

EV/EBITDA

18.57

EV/Sales

9.51

Revenue

$5.99B

EBIT

$2.96B

EBITDA

$3.07B

Free cash flow

$2.98B

Per share
Balance sheet
Liquidity

EPS

$10.36

Free cash flow per share

$11.44

Book value per share

$31.23

Revenue per share

$23.01

TBVPS

$38.02

Total assets

$11.3B

Total liabilities

$3.17B

Debt

$546.51M

Equity

$8.13B

Working capital

$5.45B

Debt to equity

0.07

Current ratio

3.72

Quick ratio

3.46

Net debt/EBITDA

-1.57

Margins
Efficiency
Dividend

EBITDA margin

51.2%

Gross margin

88%

Net margin

44.9%

Operating margin

44.7%

Return on assets

27.8%

Return on equity

38.2%

Return on invested capital

101.3%

Return on capital employed

31.8%

Return on sales

49.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

-0.44%

1 week

5.34%

1 month

1.15%

1 year

1.27%

YTD

0.53%

QTD

0.53%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$5.99B

Gross profit

$5.27B

Operating income

$2.68B

Net income

$2.69B

Gross margin

88%

Net margin

44.9%

The operating margin has soared by 108% YoY and by 15% QoQ

The gross profit has soared by 68% YoY and by 11% from the previous quarter

VRTX's revenue has soared by 66% YoY and by 11% QoQ

Vertex Pharmaceuticals's net income has increased by 29% QoQ and by 25% YoY

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

22.93

P/B

7.61

P/S

10.33

EV/EBIT

19.24

EV/EBITDA

18.57

EV/Sales

9.51

The price to earnings (P/E) is 39% less than the last 4 quarters average of 37.8

The EPS has increased by 29% since the previous quarter and by 23% year-on-year

The equity has soared by 55% YoY and by 8% from the previous quarter

The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 14.8 and 19% less than its last 4 quarters average of 9.4

VRTX's revenue has soared by 66% YoY and by 11% QoQ

The price to sales (P/S) is 27% less than the 5-year quarterly average of 14.1 and 21% less than the last 4 quarters average of 13.0

How efficient is Vertex Pharmaceuticals business performance

The return on sales has surged by 113% year-on-year and by 17% since the previous quarter

The return on invested capital rose by 27% since the previous quarter

VRTX's return on assets is up by 17% since the previous quarter but it is down by 11% year-on-year

The return on equity has grown by 16% since the previous quarter but it has declined by 13% year-on-year

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's total assets has surged by 50% YoY and by 11% QoQ

The total liabilities has increased by 40% YoY and by 17% QoQ

VRTX's debt is 93% lower than its equity

The equity has soared by 55% YoY and by 8% from the previous quarter

VRTX's debt is down by 10% YoY but it is up by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.